

CLAIMS

1. A transdermal delivery system (TDS) comprising a backing layer inert to the components of the matrix, a self-adhesive matrix containing rotigotine and a protective foil or sheet to be removed prior to use, characterized in that the self-adhesive matrix consists of a solid or semi-solid semi-permeable polymer
  - (1) wherein rotigotine in its free base form has been incorporated,
  - (2) which is saturated with rotigotine and contains said rotigotine as a multitude of microreservoirs within the matrix,
  - (3) which is highly permeable for the free base of rotigotine,
  - (4) which is impermeable for the protonated form of rotigotine,
  - (5) wherein the maximum diameter of the microreservoirs is less than the thickness of the matrix.
2. The TDS according to claim 1, characterized in that the mean diameter of the microreservoirs is in the range of 0.5 to 20  $\mu\text{m}$ .
3. The TDS according to claim 1, characterized in the self-adhesive matrix being free of particles that can absorb salts or rotigotine at the TDA/skin interface.
4. The TDS according to claim 1, characterized in that the polymer matrix comprises a silicone-type sensitive adhesive.

5. The TDS according to claim 1, characterized in that the polymer matrix comprises two or more silicone-type pressure sensitive adhesives as the main adhesive components.
6. The TDS according to claim 5, wherein the silicone type pressure sensitive adhesive is a blend of a high tack silicone type pressure sensitive adhesive comprising polysiloxane with a resin and a medium tack silicone type pressure sensitive adhesive comprising polysiloxane with a resin.
7. Method for treatment of a patient suffering from a disease treatable by rotigotine by applying the TDS according to claim 1 to the skin of the patient.